UniQure 的基因疗法显示，首位耐药性癫痫患者的癫痫发作减少了 92%。 UniQure's gene therapy shows 92% seizure reduction in first patient with drug-resistant epilepsy.

基因治疗公司 UniQure 报告称，首例接受其实验性疗法 AMT-260 治疗耐药性内侧颞叶癫痫 （MTLE） 的患者在五个月内癫痫发作减少了 92%，没有严重的副作用。 UniQure, a gene therapy company, reported that the first patient treated with their experimental therapy, AMT-260, for drug-resistant mesial temporal lobe epilepsy (MTLE) saw a 92% reduction in seizures within five months, with no serious side effects. 这种疗法是一次性,体内基因治疗,旨在减少对药物不反应的患者的发作. The therapy is a one-time, in-vivo gene treatment aimed at reducing seizures in patients who do not respond to drugs. GENTLE试验是第一阶段/IIa研究,评价AMT-260的安全和功效,需要更多参加者提供进一步数据,以取得更全面的结果。 The GenTLE trial, a Phase I/IIa study, evaluates the safety and efficacy of AMT-260, with further data from additional participants needed for more comprehensive results.